| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 02/15/2000 | US6025488 Formulations and methods of reducing toxicity of antineoplastic agents |
| 02/15/2000 | US6025399 Method of producing neuromuscular block by the use of tetra-propyl or tetrabutylammonium compounds |
| 02/15/2000 | US6025391 Enteric-coated pharmaceutical compositions of mycophenolate |
| 02/15/2000 | US6025389 A mineral oil, one or more fatty alcohols or fatty esters, a polyoxyethylene ether or ester surfactant, xanthan gum, water and a method for treating a bacterial infection using said composition. |
| 02/15/2000 | US6025369 N-methyl-D-aspartate (NMDA) receptor blockers for the prevention of atherosclerosis |
| 02/15/2000 | US6025340 Surface expression of enzyme in gene directed prodrug therapy |
| 02/15/2000 | US6025204 Diagnostic method for detection of placental-derived prostate growth factors |
| 02/15/2000 | US6025180 Asp1 |
| 02/15/2000 | US6025156 Amino acid sequence; for discovery of antibiotics, bactericides, bacteristats against staphylococcus infections |
| 02/15/2000 | US6025151 Administering compounds to treat a non-swine subject for elevated platelet derived growth factor levels, jun kinase, c-jun or inflammatory cytokines, or activation of nf-kappab or nf-kappab p65 or neutrophil infiltration |
| 02/15/2000 | US6025147 Inhibitors of interleukin-1 β converting enzyme |
| 02/15/2000 | US6024978 Oral drug composition with lipophilic compounds |
| 02/15/2000 | US6024959 Pharmaceutical composition containing pectin and a phospholipid used as an antidiarrheal and antiulcer agent |
| 02/15/2000 | US6024957 Immunomodulators and methods for the prevention and reversal of organ transplant rejection using same |
| 02/15/2000 | US6024941 Vitamin a and stabilizers |
| 02/15/2000 | CA2154730C Synergetic blend compositions between at least one rxr specific ligand and at least one rar- specific ligand; uses thereof |
| 02/14/2000 | CA2280061A1 Method of prevention and treatment of multiple sclerosis with varicella zoster immune globulin |
| 02/12/2000 | CA2248989A1 Novel compounds |
| 02/10/2000 | WO2000007014A2 Leptin-mediated gene-induction |
| 02/10/2000 | WO2000006769A2 Human ccr-2 gene polymorphisms |
| 02/10/2000 | WO2000006768A1 Genetic polymorphisms in the human neurokinin 1 receptor gene and their uses in diagnosis and treatment of diseases |
| 02/10/2000 | WO2000006767A1 Genetic polymorphisms in the human neurokinin 2 receptor gene and their use in diagnosis and treatment of diseases |
| 02/10/2000 | WO2000006738A2 NUCLEIC ACIDS AND PROTEINS FROM $i(STREPTOCOCCUS PNEUMONIAE) |
| 02/10/2000 | WO2000006737A2 Streptococcus pneumoniae proteins and nucleic acid molecules |
| 02/10/2000 | WO2000006730A2 Human cytoskeletal proteins |
| 02/10/2000 | WO2000006729A1 Kdel receptor inhibitors |
| 02/10/2000 | WO2000006716A1 Growth differentiation factor-11 |
| 02/10/2000 | WO2000006712A2 Protein tyrosine phosphatase-1b (ptp-1b) deficient mice and uses thereof |
| 02/10/2000 | WO2000006709A1 Human protein kinase h2lau20 |
| 02/10/2000 | WO2000006694A2 Compound and method for the prevention and/or the treatment of allergy |
| 02/10/2000 | WO2000006601A1 Isoforms of human calcium sensing receptor |
| 02/10/2000 | WO2000006598A1 Endogenous retrovirus tumor associated nucleic acids and antigens |
| 02/10/2000 | WO2000006597A2 Endogenous constitutively activated g protein-coupled orphan receptors |
| 02/10/2000 | WO2000006579A2 Pyrrolo[2,1-b][1,3]benzothiazepines with atypical antipsychotic activity |
| 02/10/2000 | WO2000006569A1 Substituted pyrazole derivatives condensed with six-membered heterocyclic rings |
| 02/10/2000 | WO2000006568A1 Substituted pyrazole derivatives |
| 02/10/2000 | WO2000006567A1 3-(4-amino-5-ethylpyrimidine-2-yl)-1-(2-fluorobenzyl)-1h-pyrazolo[3,4-b]pyridine |
| 02/10/2000 | WO2000006554A1 Lipid-lowering quinazoline derivative |
| 02/10/2000 | WO2000006545A1 High affinity ligands for nociceptin receptor orl-1 |
| 02/10/2000 | WO2000006534A1 Compounds and compositions for delivering active agents |
| 02/10/2000 | WO2000006243A2 Absorbable brachytherapy and chemotherapy delivery devices and methods |
| 02/10/2000 | WO2000006206A1 Compositions and methods for the treatment and diagnosis of cardiovascular disease |
| 02/10/2000 | WO2000006188A1 Hair growth/maintenance compositions and methods involving the same |
| 02/10/2000 | WO2000006187A2 Modulation of apoptosis |
| 02/10/2000 | WO2000006184A1 Pulmonary delivery of active agents |
| 02/10/2000 | WO2000006183A1 C7F2-A NOVEL POTASSIUM CHANNEL β-SUBUNIT |
| 02/10/2000 | WO2000006171A1 Antioxidant composition and method of treating diseases using same |
| 02/10/2000 | WO2000006169A1 Integrin receptor antagonists |
| 02/10/2000 | WO2000006161A1 Prevention of migraine recurrence |
| 02/10/2000 | WO2000006160A1 Treating depression with a combination of fluoxetine (prozac), pindolol (visken) and buspirone (buspar) |
| 02/10/2000 | WO2000006145A1 Methods for treating conditions modulated by lactosylceramide |
| 02/10/2000 | WO2000006144A1 Pharmaceutical compositions and methods for managing scalp conditions |
| 02/10/2000 | WO2000006142A1 Injectable propofol formulations |
| 02/10/2000 | WO2000006140A2 Use of moclobemide for treating certain phsychiatric and medical disorders |
| 02/10/2000 | WO2000006139A2 Use of moclobemide and metabolites for treating and preventing substance abuse |
| 02/10/2000 | WO2000006138A2 Use of moclobemide for treating pain and other diseases |
| 02/10/2000 | WO2000006135A2 Cholinergic agents in the treatment of presbyopia |
| 02/10/2000 | WO2000006134A2 Use of l-carnitine and its alkanoyl derivatives in the preparation of medicaments with anticancer activity |
| 02/10/2000 | WO2000006126A1 Rapidly disintegrable solid preparation |
| 02/10/2000 | WO2000006123A1 Microparticles with adsorbent surfaces, methods of making same, and uses thereof |
| 02/10/2000 | WO2000006116A1 Pharmaceutical compositions and methods for managing skin conditions |
| 02/10/2000 | WO2000006082A2 Treatment of anxiety disorders |
| 02/10/2000 | WO2000006032A1 Ultrasonic enhancement of drug injection |
| 02/10/2000 | WO2000000825A3 Detection and modulation of cellular immunity to immune privileged antigens |
| 02/10/2000 | WO2000000510A8 Growth factor modulators |
| 02/10/2000 | WO1999063944A3 Novel therapeutic agents that modulate estrogen receptors |
| 02/10/2000 | WO1999061600A3 A method of modulating the efficiency of translation termination and degradation of aberrant mrna involving a surveillance complex comprising human upf1p, eucaryotic release factor 1 and eucaryotic release factor 3 |
| 02/10/2000 | WO1999058678A3 Antibodies to dendritic cells and human dendritic cell populations and uses thereof |
| 02/10/2000 | WO1999058139A3 Methods for detecting and inhibiting angiogenesis |
| 02/10/2000 | WO1999049039A3 GFRα3 AND ITS USES |
| 02/10/2000 | WO1999045910A3 Methods and compositions for treating and preventing mucositis |
| 02/10/2000 | WO1999045126A3 Enhanced prodrug activation |
| 02/10/2000 | WO1999042481A3 AGENTS FOR TREATING HUMAN ILLNESSES BASED ON β-CATENIN, AND THE PRODUCTION AND USE THEREOF |
| 02/10/2000 | CA2581111A1 Rapidly disintegrable solid preparation |
| 02/10/2000 | CA2525555A1 Rapidly disintegrable solid preparation |
| 02/10/2000 | CA2339096A1 Modulation of apoptosis |
| 02/10/2000 | CA2339093A1 Cholinergic agents in the treatment of presbyopia |
| 02/10/2000 | CA2339071A1 Substituted pyrazole derivatives condensed with six-membered heterocyclic rings |
| 02/10/2000 | CA2338825A1 Lipid-lowering quinazoline derivative |
| 02/10/2000 | CA2338797A1 Hair growth/maintenance compositions and methods involving the same |
| 02/10/2000 | CA2338740A1 Treatment of anxiety disorders |
| 02/10/2000 | CA2338643A1 Protein tyrosine phosphatase-1b (ptp-1b) deficient mice and uses thereof |
| 02/10/2000 | CA2338396A1 Ultrasonic enhancement of drug injection |
| 02/10/2000 | CA2338330A1 Use of moclobemide for treating certain phsychiatric and medical disorders |
| 02/10/2000 | CA2338327A1 Use of moclobemide for treating pain and other diseases |
| 02/10/2000 | CA2338326A1 Use of moclobemide and metabolites for treating and preventing substance abuse |
| 02/10/2000 | CA2338275A1 Integrin receptor antagonists |
| 02/10/2000 | CA2337692A1 Kdel receptor inhibitors |
| 02/10/2000 | CA2336549A1 Methods for treating conditions modulated by lactosylceramide |
| 02/10/2000 | CA2336543A1 Isoforms of human calcium sensing receptor |
| 02/10/2000 | CA2336536A1 Growth differentiation factor-11 |
| 02/10/2000 | CA2336530A1 Compositions and methods for the treatment and diagnosis of cardiovascular disease |
| 02/10/2000 | CA2335656A1 Human cytoskeletal proteins |
| 02/10/2000 | CA2335643A1 C7f2-a novel potassium channel .beta.-subunit |
| 02/09/2000 | EP0978287A1 MEDICINAL COMPOSITION CONTAINING gp34 BINDING INHIBITOR AS THE ACTIVE INGREDIENT |
| 02/09/2000 | EP0977893A1 Reagents and methods useful for detecting diseases of the prostate |
| 02/09/2000 | EP0977892A1 Methods and compositions for use in modulating expression of matrix metalloproteinase genes |
| 02/09/2000 | EP0977887A2 Member of the tnf family useful for treatment and diagnosis of disease |
| 02/09/2000 | EP0977850A1 Edg-1-like receptor |
| 02/09/2000 | EP0977848A1 Human theta subunit of the gaba-a receptor |